Skip to content

Phenylpropanolamine

RESPIRATORY SYSTEM

Also known as: (+/-)-phenylpropanolamine, norephedrine, phenylpropanolamine HCl, phenylpropanolamine hydrochloride, phenylpropanolamine polistirex, propadrine

OfmFDA approvedATC R01BA01ATC R01BA51

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Phenylpropanolamine is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2000. DrugCentral lists 13 molecular targets, including SLC6A2, SLC6A3 and Adra2b. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Cough.

  • Approval status: ofm (first approved 2000 by the FDA).
  • Molecular targets: SLC6A2, SLC6A3, Adra2b and ADRA2C (13 listed in DrugCentral).
  • Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Cough and Influenza-like symptoms and others.
  • ATC code: R01BA01 (Sympathomimetics).
  • Molecular formula: C9H13NO; molecular weight 151.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (12)

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Common cold
  • Cough
  • Influenza-like symptoms
  • Nasal congestion
  • Nasal discharge
  • Rhinitis
  • Seasonal allergic rhinitis
  • Sinus headache
  • Sneezing
  • Vasomotor rhinitis

Off-label uses (1)

  • Obesity

Contraindications (87)

  • Acidosis
  • Acute abdominal pain
  • Acute erosive gastritis
  • Acute hepatitis
  • Acute nephropathy
  • Acute pancreatitis
  • Agoraphobia
  • Alcohol intoxication
  • Alcohol withdrawal delirium
  • Alcoholism
  • Anemia
  • Anemia due to enzyme deficiency
  • Angle-closure glaucoma
  • Arterial thrombosis
  • Arteriosclerotic vascular disease
  • Asthenia
  • Benign intracranial hypertension
  • Benign prostatic hyperplasia
  • Bladder outflow obstruction
  • Bradycardia
  • Breastfeeding (mother)
  • Central nervous system depression
  • Chronic heart failure
  • Chronic idiopathic constipation
  • Chronic obstructive lung disease
  • Coma
  • Conduction disorder of the heart
  • Constipation
  • Cor pulmonale
  • Decreased respiratory function
  • + 57 more

Mechanism & targets

Molecular targets (13)

TargetGeneActionActivity
Sodium-dependent noradrenaline transporterSLC6A2unknownKi 7.82
Sodium-dependent dopamine transporterSLC6A3unknownKi 7.17
Alpha-2B adrenergic receptorAdra2bunknownKi 6.58
Alpha-2C adrenergic receptorADRA2CunknownKi 6.58
Alpha-2A adrenergic receptorADRA2AunknownKi 6.56
Alpha-2B adrenergic receptorADRA2BunknownKi 6.40
Muscarinic acetylcholine receptor M1CHRM1unknownKi 5.17
5-hydroxytryptamine receptor 7HTR7unknownKi 5.16
Alpha-1D adrenergic receptorAdra1dunknownKi 5.07
Alpha-1B adrenergic receptorADRA1BunknownKi 5.02
Alpha-1A adrenergic receptorAdra1aunknownKi 5.01
Potassium voltage-gated channel subfamily H member 2KCNH2unknown—
Alpha-1A adrenergic receptorADRA1Aagonist—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2000-09-29FDA—ALPHARMA US PHARMS

ATC classification

ATC codeTherapeutic hierarchy
R01BA01RESPIRATORY SYSTEM › NASAL PREPARATIONS › NASAL DECONGESTANTS FOR SYSTEMIC USE › Sympathomimetics
R01BA51RESPIRATORY SYSTEM › NASAL PREPARATIONS › NASAL DECONGESTANTS FOR SYSTEMIC USE › Sympathomimetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Toxicity to various agents75.2
Sudden cardiac death42.2
Maternal exposure before pregnancy41.2

Chemical structure

Molecular formulaC9H13NO
Molecular weight151.21 g/mol
CAS number14838-15-4
InChIKeyDLNKOYKMWOXYQA-UHFFFAOYSA-N
PubChem CID10297
CC(N)C(O)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Phenylpropanolamine used for?

DrugCentral lists the following indications for Phenylpropanolamine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Cough, Influenza-like symptoms, Nasal congestion, Nasal discharge and Rhinitis and others.

How does Phenylpropanolamine work?

Its molecular targets in DrugCentral include SLC6A2, SLC6A3, Adra2b and ADRA2C.

When was Phenylpropanolamine first approved?

Phenylpropanolamine was first approved by the FDA in 2000.

What is the chemical formula of Phenylpropanolamine?

Phenylpropanolamine has the molecular formula C9H13NO and a molecular weight of 151.21 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2000-09-29
AgencyFDA
Targets13
Indications12
FormulaC9H13NO
DrugCentral ID2149
Interactive profile